30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction…
Read More
CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction…
Read More
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric”…
Read More
CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders,…
Read More
CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders,…
Read More
– Next Generation Psilocin Prodrug, EB-373, Nominated to Advances to IND-Enabling Studies – -First Generation EVM101 Program for Cancer Related Distress has been discontinued – CAMBRIDGE, Mass. –…
Read More
